Table S5. Distribution of specimen source/s, phenotypic DST method/s used, total number of isolates, and phenotypic antibiotics monoresistance rate, MDR and XDR rate of *M. tb* complex across African countries, January 2007- December 2018

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Country (number of studies)** | **Year** | Specimens Source/s | Phenotypic DST Method/s used | **Sample size, n (%)** | **Total positive samples, n (%)** | **Frequency and proportions of antibiotics to which strains were mono-resistant, (n (%))** | | | | | | | | | | | | | | | **Total Resistance rate** | | **MDR/XDR** | | **Total Resistance rate** | **Ref(s)** | Reference |
| **INH** | **RIF** | **PZA** | **EMB** | **RFB** | **STM** | **ETA** | **CAP** | **KAM** | **AMK** | **OFL** | **CIP** | **LEV** | **MOX** | **NOR** |  | **MDR n (%)** | | **XDR n (%)** | |  |  |
| Algeria (1) | 2015 | Sputum & extrapulmonary samples | Proportion method on L-J medium | 129 | 126 | 1 | 6 | - | - | - | 2 | - | - | - | - | - | - | - | - | - | 13 | 7 | | - | | [1] | (Ifticene et al., 2015) |
| Resistance rate |  | **126** | **1(0.8)** | **6(4.8)** |  |  |  |  |  |  | **2(1.6)** |  |  |  |  |  |  |  |  | **13 (10.3)** | **7 (5.6)** | | **-** | |
| Angola (1) | 2017 | Sputum | BACTECTM MGITTM 960 system | 106 | 89 | 6 | 1 | - | - | - | 5 | - | - | - | - | - | - | - | - | - | 22 | 4 | | - | | [2] | (Perdigao et al., 2016) |
| Resistance rate |  | **89** | **6(6.7)** | **1(1.1)** |  |  |  | **5(5.6)** |  |  |  |  |  |  |  |  |  | **22(24.7)** | **4(4.5)** | **-** |  | |  | |
| Benin (2) | 2009 | Sputum | Proportion method on L-J medium | 194 | 143 | 3 | - | - | 2 | - | 28 | - | - | - | - | - | - | - | - | - | 34 | 2 | | - | | [3] | (Affolabi et al., 2009) |
| 2017 | Sputum | Proportion method on LJ medium | 100 | 100 | 2 | 1 | - | 2 | - | 14 | - | 0 | 1 | 0 | 2 | - | - | - | - | 40 | 12 | | 0 | | [4] | (Affolabi et al., 2017) |
| Resistance rate |  | **243** | **5(2.1)** | **1(0.4)** |  | **4(1.6)** |  | **42(17.3)** |  |  | **1(0.4** |  | **2(0.8)** |  |  |  |  | **74(30.5)** | **14(5.8)** | **-** |  | |  | |
| Burkina Faso (2) | 2009 | Sputum | BACTECTM MGITTM 960 system | 108 | 60 | 7 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 34 | 25 | | - | | [5] | (Miotto et al., 2009) |
| 2007 | Sputum | Radiometric broth method (BACTEC; Becton Dickinson Diagnostic Systems) | 120 | 61 | 2 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 3 | 1 | | - | | [6] | (Godreuil et al., 2007) |
| Resistance rate |  | **121** | **9(7.4)** |  |  |  |  |  |  |  |  |  |  |  |  |  |  | **37(30.6)** | **26(21.5)** | **-** |  | |  | |
| Cameroon (2) | 2014 | Sputum | Indirect proportion method on L-J medium | 163 | 163 | 44 | 7 | - | 2 | - | 27 | - | - | - | - | - | - | - | - | - | 63 | - | | - | | [7] | (Tekwu et al., 2014) |
| 2016 | Sputum | Indirect proportion method on L-J slants | 437 | 437 | 13 | 2 | - | 0 | - | 12 | - | - | - | - | - | - | - | - | - | 38 | 6 | | - | | [8] | (Koro Koro et al., 2016) |
| Resistance rate |  | **600** | **57(9.5)** | **9(1.5)** |  | **2(0.3)** |  | **37(6.2)** |  |  |  |  |  |  |  |  |  | **101(16.8)** | **6(1)** |  |  | |  | |
| Chad (1) | 2017 | Sputum | BACTEC MGIT 960 system | 593 | 311 | 42 | 17 | - | - | - | - | - | - | - | - | - | - | - | - | - | 73 | 14 | | - | | [9] | (Ba Diallo et al., 2017) |
| Resistance rate |  | **311** | **42(13.5)** | **17(5.5)** |  |  |  |  |  |  |  |  |  |  |  |  |  | **73(23.5)** |  |  |  | |  | |
| Congo (2) | 2014 | Sputum | BACTECTM MGITTM 960 system | 114 | 46 | 4 | 0 | - | - | - | 1 | \_ | - | - | - | 0 | - | - | 0 | - | 21 | 15 | | - | | [10] | (Aubry et al., 2014) |
| 2017 | Sputum | BACTEC MGIT 960 (Becton, Dickinson & Company, Franklin Lakes, NJ, USA) | 74 | 74 | 0 | 0 | 0 | 0 | - | 0 | 1 | - | - | - | - | - | - | - | - | 3 | 2 | | - | | [11] | (Malm et al., 2017) |
| Resistance rate |  | **120** | **4(3.3)** |  |  |  |  | **1(0.8)** | **1(0.8)** |  |  |  |  |  |  |  |  | **25(20.8)** | **17(14.2)** | **-** |  | |  | |
| Côte d’Ivoire (3) | 2015 | Sputum | BACTECTM MGITTM 960 system | 2 | 2 | 2 | 2 | - | 2 | - | 1 | 2 | - | 2 | 2 | 2 | - | - | - | - | 2 | - | | - | | [12] | (N'Guessan et al., 2015) |
| 2016 | Sputum | BACTECTM MGITTM 960 system | 63 | 63 | 59 | 56 | - | 16 | - | 48 | - | - | - | - | - | - | - | - | - | 60 | 55 | | - | | [13] | (N'Guessan Kouassi et al., 2016) |
| 2008 | Sputum | proportion method with L–J | 196 | 196 | 24 | 7 | - | - | - | - | - | - | - | - | - | - | - | - | - | 24 | 7 | | - | | [14] | (N'Guessan et al., 2 |
| Resistance rate |  | **261** | **85(32.6)** | **65(24.9)** |  | **18(6.9)** |  | **49(18.8)** | **2(0.8)** |  | **2(0.8)** | **2(0.8)** | **2(0.8)** |  |  |  |  | **86(33)** | **62(23.8)** | **-** |  | |  | |
| Djibouti (1) | 2016 | Sputum | Proportion method on  L-J medium | 32 | 32 | 1 | 0 | - | - | - | 1 | - | - | - | - | - | - | - | - | - | 29 | 23 | | 4 | | [15] | (Millan-Lou et al., 2016) |
| Resistance rate |  | **32** | **1(3.125)** |  |  |  |  | **1(3.125)** |  |  |  |  |  |  |  |  |  | **29(90.6)** | **23(71.9)** | **4(12.5)** |  | |  | |
| Egypt (2) | 2009 | Sputum | Standard agar proportion method. | 155 | 155 | 6 | 3 | 2 | 2 | - | 21 | - | - | - | - | - | - | - | - | - | 76 | 25 | | - | | [16] | (Abbadi et al., 2009) |
| 2009 | Sputum | Radiometric method (BACTEC 460 system) | 153 | 153 | 10 | 6 | - | 4 | - | 4 | - | - | - | - | - | - | - | - | - | 50 | 5 | | - | | [17] | (Abdelaal et al., 2009) |
| Resistance rate |  | **308** | **16(5.2)** | **9(2.3)** | **2(0.6)** | **6(1.9)** |  | **25(8.1)** |  |  |  |  |  |  |  |  |  | **126(40.9)** | **30(9.7)** | **-** |  | |  | |
| Ethiopia (9) | 2017 | Sputum | BACTEC MGIT 960 system | 274 | 90 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 78 | 30 | | - | | [18] | (Meaza et al., 2017) |
| 2013 | lymph node aspirates | BacT/AlerT 3D system | 226 | 226 | 6 | 1 | - | 2 | - | - | - | - | - | - | - | - | - | - | - | 13 | 2 | | - | | [19] | (Biadglegne et al., 2013) |
| 2012 | Sputum | BacT/ALERT 3D system. | 260 | 260 | 33 | 15 | - | 8 | - | - | - | - | - | - | - | - | - | - | - | 69 | 13 | | - | | [20] | (Tessema et al., 2012) |
| 2016 | Sputum | BACTECTM MGITTM 960 system | 127 | 109 | 8 | 6 | - | 5 | - | 17 | - | - | - | - | - | - | - | - | - | 27 | 4 | | - | | [21] | (Ali et al., 2016) |
| 2016 | Sputum | Proportion method with L–J | 279 | 279 | 24 | 8 | - | - | - | - | - | - | - | - | - | - | - | - | - | 35 | 3 | | - | | [22] | (Bedewi Omer et al., 2016) |
| 2018 | Sputum | Proportion method with L–J | 105 | 86 | 4 | 0 | - | 2 | - | 2 | - | - | - | - | - | - | - | - | - | 20 | 0 | | - | | [23] | (Tilahun et al., 2018) |
| 2015 | pleural, peritoneal & synovial fluids | Modified proportion method | 59 | 37 | 3 | 8 | - | 1 | - | 2 | - | - | - | - | - | - | - | - | - | 16 | - | | - | | [24] | (Korma et al., 2015) |
| 2015 | Sputum | BACTECMGIT960 system | 240 | 231 | 8 | 3 | - | - | - | 22 | - | - | - | - | - | - | - | - | - | 39 | 2 | | - | | [25] | (Yimer et al., 2015) |
| 2015 | Sputum | Indirect proportion method on L-J media | 92 | 90 | 1 | 0 | - | 0 | - | 24 | - | - | - | - | - | - | - | - | - | 30 | 4 | | - | | [26] | (Getahun et al., 2015) |
| Resistance rate |  | **1408** | **87(6.2)** | **41(2.9)** |  | **18(1.3)** |  | **67(4.8)** |  |  |  |  |  |  |  |  |  | **327(23.2)** | **58(4.11)** | **-** |  | |  | |
| Ghana (1) | 2011 | Sputum | Indirect proportion method on L-J slants | 162 | 124 | 16 | 8 | - | 5 | - | 39 | - | - | - | - | - | - | - | - | - | 47 | 4 | | - | | [27] | (Yeboah-Manu et al., 2011) |
| Resistance rate |  | **124** | **16(12.9)** | **8(6.5)** |  | **5(4)** |  | **39(31.5)** |  |  |  |  |  |  |  |  |  | **47(37.9)** | **4(3.2)** |  |  | |  | |
| Guinea (1) | 2015 | Sputum | L-J slopes using the proportion method | 359 | 359 | 10 | 2 | - | - | - | 17 | - | - | - | - | - | - | - | - | - | 82 | 9 | | - | | [28] | (Ejo et al., 2015) |
| Resistance rate |  | **359** | **10(2.8)** | **2(0.6)** |  |  |  | **17(4.7)** |  |  |  |  |  |  |  |  |  | **82(22.8)** | **9(2.5)** |  |  | |  | |
| Morocco (3) | 2009 | Sputum | Proportion method on L–J slants | 199 | 199 | 5 | - | - | 26 | - | 58 | - | - | - | - | - | - | - | - | - | 66 | - | | - | | [29] | (Chaoui et al., 2009) |
| 2015 | Induced Sputum samples | BACTECMGIT960 system | 168 | 168 | 10 | 0 | - | 1 | - | 1 | - | - | - | - | - | - | - | - | - | 19 | 5 | | - | | [30] | (Bouklata et al., 2015) |
| 2013 | Sputum | Proportion method on L–J Medium | 208 | 208 | 7 | 6 | - | 1 | - | 12 | - | - | 2 | - | - | - | - | - | - | 106 | 56 | | - | | [31] | (Chaoui et al., 2014) |
| Resistance rate |  | **575** | **22(16.2)** | **6(1)** |  | **28(4.9)** |  | **71(12.3)** |  |  | **2(0.3)** |  |  |  |  |  |  | **191(33.2)** | **61(10.6)** | **-** |  | |  | |
| Rwanda (1) | 2012 | Sputum | Indirect proportion method on L-J media | 151 | 151 | 1 | 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | 84 | 64 | | - | | [32] | (Gafirita et al., 2012) |
| Resistance rate |  | **151** | **1(0.7)** | **2(1.3)** |  |  |  |  |  |  |  |  |  |  |  |  |  | **84(55.6)** | **64(42.4)** |  |  | |  | |
| Sierra Leone (2) | 2012 | Sputum | BACTEC 460 system | 97 | 97 | 32 | 16 | 10 | 15 | - | 40 | - | - | - | - | - | - | - | - | - | 50 | 12 | | - | | [33] | (Feuerriegel et al., 2012) |
| 2008 | Sputum | BACTEC 460 system | 97 | 97 | 8 | 1 | - | - | - | 15 | - | - | - | - | - | - | - | - | - | 50 | 11 | | - | | [34] | (Homolka et al., 2008) |
| Resistance rate |  | **194** | **40(20.6)** | **17(8.8)** | **10(5.2)** | **15(7.7)** |  | **55(28.4)** |  |  |  |  |  |  |  |  |  | **100(51.5)** | **23(11.9)** |  |  | |  | |
| South Africa (13) | 2015 | Sputum | BACTEC MGIT (BD Biosciences, San Jose, CA) | 1240 | 1113 | 62 | 7 | - | - | - | - | - | - | - | - | - | - | - | - | - | 115 | 46 | | - | | [35] | (Mathema et al., 2015) |
| 2015 | Sputum | MGIT 960 system | 88 | 88 | - | - | 28 | - | - | - | - | - | - | - | - | - | - | - | - | 28 | - | | - | | [36] | (Maningi et al., 2015) |
| 2017 | Sputum | MGIT 960 system | 100 | 97 | 11 | 33 | - |  | - | 0 | - | - | 3 | - | 9 | - | - | - | - | 97 | 53 | | - | | [37] | (Maningi et al., 2017) |
| 2015 | Sputum | MGIT proportion method | 500 | 500 | 48 | 39 | - | - | - | - |  | - | - | - | - | - | - | - | - | 285 | 108 | | 58 | | [38] | (Kamudumuli et al., 2015) |
| 2008 | Sputum | MGIT 960 system | 240 | 240 | 44 | 11 | - | 4 | - | 7 | - | - | - | - | - | - | - | - | - | 240 | 143 | | - | | [39] | (Green et al., 2008) |
| 2012 | Sputum | MGIT 960 system | 529 | 529 | 35 | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | 58 | 23 | | - | | [40] | (Dorman et al., 2012) |
| 2016 | Sputum | Minimum inhibitory concentrations Sensititre MYCOTB plate (TREK Diagnostics, Cleveland, OH, USA | 211 | 189 | 0 | 51 | - | - | 138 | - | - | - | - | - | - | - | - | - | - | 189 | 189 | | - | | [41] | (Rukasha et al., 2016) |
| 2015 | Sputum | Agar proportion method | 1000 | 994 | 129 | 70 | - | - | - | - | - | - | - | - | - | - | - | - | - | 994 | 694 | | 29 | | [42] | (Niehaus et al., 2015) |
| 2014 | Sputum | MIC test | 60 | 56 | - | - | - | - | - | -- | - | - | - | - | 0 | 0 | - | 0 | - | 46 | 16 | | 30 | | [43] | (Dookie et al., 2014) |
| 2014 | Sputum | Agar-dilution proportion method | 190 | 190 | 190 | 1 | 0 | - | - | - | 0 | - | 0 | 0 | 0 | - | - | - | - | 190 | 189 | | 157 | | [44] | (Bhembe et al., 2014) |
| 2013 | Sputum | Culture based DST | 340 | 340 | 31 | 53 | - | - | - | - | - | - | - | -- | - | - | - | - | - | 286 | 101 | | 48 | | [45] | (de Vos et al., 2013) |
| 2013 | Sputum | Indirect proportion method with the BACTEC MGIT 960 (BD Bioscience, Sparks, MD, USA) | 651 | 651 | 0 | 0 | - | 0 | - | 0 | 0 | 0 | - | 0 | 0 | - | - | - | - | 342 | 342 | | 84 | | [46] | (Klopper et al., 2013) |
| 2012 | Sputum | BACTEC MGIT 960 system | 111 | 111 | 2 | 0 | - | 8 | - | 0 | - | - | - | - | - | - | - | - | - | 77 | 12 | | 2 | | [47] | (Sirgel et al., 2012) |
| Resistance rate |  | **5098** | **552(10.8)** | **266(5.2)** | **28(0.5)** | **12(0.2)** | **138(2.7)** | **7(0.1)** |  |  | **3(0.1)** |  | **9(0.2)** |  |  |  |  | **2947(57.8)** | **1916(37.6)** | **408(8)** |  | |  | |
| Sudan (1) | 2017 | Sputum | Conventional proportional method on L-J MEDIUM | 100 | 75 | 21 | 22 |  | 15 | - | - | - | - | - | - | - | - | - | - | - | 58 | 15 | | - | | [48] | (Sabeel et al., 2017) |
| Resistance rate |  | **75** | **21(28)** | **22(29.3)** |  | **15(20)** |  |  |  |  |  |  |  |  |  |  |  | **58(77.3)** | **15(20)** | **-** |  | |  | |
| Tanzania (1) | 2007 | Sputum/broncho-alveolar lavage | Phenotyping test | 130 | 111 | 7 | 0 | - | 0 | - | 1 | - | - | - | - | - | - | - | - | - | 12 | 3 | | - | | [49] | (Kibiki et al., 2007) |
| Resistance rate |  | **111** | **7(6.3)** |  |  |  |  | **1(0.9)** |  |  |  |  |  |  |  |  |  | **12(10.8)** | **3(2.7)** |  |  | |  | |
| Tunisia (4) | 2010 | Sputum | Conventional proportional method on L-J medium | 495 | 495 | 0 | 0 | - | - | - | 0 | 0 | - | - | - | - | 4 | - | - | - | 4 | - | | - | | [50] | (Soudani et al., 2010) |
| 2007 | Sputum | Standard-proportion agar method | 544 | 544 | 0 | 0 | - | 0 | - | 0 | - | - | - | - | - | - | - | - | - | 10 | 6 | | - | | [51] | (Soudani et al., 2007) |
| 2011 | Sputum | Proportion method | 283 | 283 | 16 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 28 | 12 | | - | | [52] | (Ben Kahla et al., 2011) |
| 2008 | sputum | Proportional method on Lowenstein–Jensen | 379 | 371 | 7 | 5 | 5 | 0 | - | 27 | - | - | - | - | - | - | - | - | - | 85 | 34 | | - | | [53] | (Namouchi et al., 2008) |
| Resistance rate |  | **1693** | **23(1.4)** | **5(0.3)** | **5(0.3)** |  |  | **27(1.6)** |  |  |  |  |  | **4(0.2)** |  |  |  | **127(7.5)** | **52(3.1)** |  |  | |  | |  |  |

***NB****:* ***INH****= Isoniazid,* ***RIF****= Rifampin,* ***PZA****= Pyrazinamide,* ***EMB****= Ethambutol,* ***RFB****= Rifabutin,* ***STM****= Streptomycin,* ***ETA****= Ethionamide,* ***CAP****= Capreomycin,* ***KAN****= Kanamycin,* ***AMK****= Amikacin,* ***OFL****= Ofloxacin,* ***CIP****= Ciprofloxacin,* ***LEV****=Levofloxacin,* ***MOX****= Moxifloxacin,* ***NOR****= Norfloxacin,* ***DST****=Drug susceptibility testing.*

**References**

1. Ifticene M, Kaidi S, Khechiba MM, Yala D, Boulahbal F. Genetic diversity of Mycobacterium tuberculosis strains isolated in Algeria: Results of spoligotyping. *Int J Mycobacteriol*. 2015;**4**(4):290-5.

2. Perdigao J, Clemente S, Ramos J, Masakidi P, Machado D, Silva C, et al. Genetic diversity, transmission dynamics, and drug resistance of Mycobacterium tuberculosis in Luanda, Angola. *Int J Mycobacteriol*. 2016;**5 Suppl 1**:S38-s9.

3. Affolabi D, Anyo G, Faihun F, Sanoussi N, Shamputa IC, Rigouts L, et al. First molecular epidemiological study of tuberculosis in Benin. *Int J Tuberc Lung Dis*. 2009;**13**(3):317-22.

4. Affolabi D, Sanoussi N, Codo S, Sogbo F, Wachinou P, Massou F, et al. First Insight into a Nationwide Genotypic Diversity of Mycobacterium tuberculosis among Previously Treated Pulmonary Tuberculosis Cases in Benin, West Africa. *Can J Infect Dis Med Microbiol*. 2017;**2017**:3276240.

5. Miotto P, Saleri N, Dembele M, Ouedraogo M, Badoum G, Pinsi G, et al. Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso. *BMC Infect Dis*. 2009;**9**:142.

6. Godreuil S, Torrea G, Terru D, Chevenet F, Diagbouga S, Supply P, et al. First molecular epidemiology study of Mycobacterium tuberculosis in Burkina Faso. *J Clin Microbiol*. 2007;**45**(3):921-7.

7. Tekwu EM, Sidze LK, Assam JP, Tedom JC, Tchatchouang S, Makafe GG, et al. Sequence analysis for detection of drug resistance in Mycobacterium tuberculosis complex isolates from the Central Region of Cameroon. *BMC Microbiol*. 2014;**14**:113.

8. Koro Koro F, Um Boock A, Kaiyven AL, Noeske J, Gutierrez C, Kuaban C, et al. Genetic Structure and Drug Susceptibility Patterns of Mycobacterium tuberculosis Complex Strains Responsible of Human Pulmonary Tuberculosis in the Major Rearing Region in Cameroon. *Biomed Res Int*. 2016;**2016**:2904832.

9. Ba Diallo A, Ossoga GW, Daneau G, Lo S, Ngandolo R, Djaibe CD, et al. Emergence and clonal transmission of multi-drug-resistant tuberculosis among patients in Chad. *BMC Infect Dis*. 2017;**17**(1):579.

10. Aubry A, Sougakoff W, Bodzongo P, Delcroix G, Armand S, Millot G, et al. First evaluation of drug-resistant Mycobacterium tuberculosis clinical isolates from Congo revealed misdetection of fluoroquinolone resistance by line probe assay due to a double substitution T80A-A90G in GyrA. *PLoS One*. 2014;**9**(4):e95083.

11. Malm S, Linguissi LS, Tekwu EM, Vouvoungui JC, Kohl TA, Beckert P, et al. New Mycobacterium tuberculosis Complex Sublineage, Brazzaville, Congo. *Emerg Infect Dis*. 2017;**23**(3):423-9.

12. N'Guessan K, Bakayoko AS, Ahui-Brou JM, Kouakou AO, Coulibaly B, Guei A, et al. Extensively drug-resistant Mycobacterium tuberculosis strains isolated in Cote d'Ivoire. *Med Mal Infect*. 2015;**45**(7):303-5.

13. N'Guessan Kouassi K, Riccardo A, Dutoziet Christian C, Andre G, Ferilaha C, Hortense SA, et al. Genotyping of mutations detected with GeneXpert. *Int J Mycobacteriol*. 2016;**5**(2):142-7.

14. N'Guessan KR, Dosso M, Ekaza E, Kouakou J, Jarlier V. Molecular characterisation of isoniazid-resistant Mycobacterium tuberculosis isolated from new cases in Lagunes region (Cote d'Ivoire). *Int J Antimicrob Agents*. 2008;**31**(5):498-500.

15. Millan-Lou MI, Olle-Goig JE, Tortola MT, Martin C, Samper S. Mycobacterial diversity causing multi- and extensively drug-resistant tuberculosis in Djibouti, Horn of Africa. *Int J Tuberc Lung Dis*. 2016;**20**(2):150-3.

16. Abbadi SH, Sameaa GA, Morlock G, Cooksey RC. Molecular identification of mutations associated with anti-tuberculosis drug resistance among strains of Mycobacterium tuberculosis. *Int J Infect Dis*. 2009;**13**(6):673-8.

17. Abdelaal A, El-Ghaffar HA, Zaghloul MH, El Mashad N, Badran E, Fathy A. Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial. *Ann Clin Microbiol Antimicrob*. 2009;**8**:4.

18. Meaza A, Kebede A, Yaregal Z, Dagne Z, Moga S, Yenew B, et al. Evaluation of genotype MTBDRplus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples. *BMC Infect Dis*. 2017;**17**(1):280.

19. Biadglegne F, Tessema B, Rodloff AC, Sack U. Magnitude of gene mutations conferring drug resistance in mycobacterium tuberculosis isolates from lymph node aspirates in ethiopia. *Int J Med Sci*. 2013;**10**(11):1589-94.

20. Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. *BMC Infect Dis*. 2012;**12**:37.

21. Ali S, Beckert P, Haileamlak A, Wieser A, Pritsch M, Heinrich N, et al. Drug resistance and population structure of M.tuberculosis isolates from prisons and communities in Ethiopia. *BMC Infect Dis*. 2016;**16**(1):687.

22. Bedewi Omer Z, Mekonnen Y, Worku A, Zewde A, Medhin G, Mohammed T, et al. Evaluation of the GenoType MTBDRplus assay for detection of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis isolates in central Ethiopia. *Int J Mycobacteriol*. 2016;**5**(4):475-81.

23. Tilahun M, Ameni G, Desta K, Zewude A, Yamuah L, Abebe M, et al. Molecular epidemiology and drug sensitivity pattern of Mycobacterium tuberculosis strains isolated from pulmonary tuberculosis patients in and around Ambo Town, Central Ethiopia. *PLoS One*. 2018;**13**(2):e0193083.

24. Korma W, Mihret A, Hussien J, Anthony R, Lakew M, Aseffa A. Clinical, molecular and drug sensitivity pattern of mycobacterial isolates from extra-pulmonary tuberculosis cases in Addis Ababa, Ethiopia. *BMC Infect Dis*. 2015;**15**:456.

25. Yimer SA, Norheim G, Namouchi A, Zegeye ED, Kinander W, Tonjum T, et al. Mycobacterium tuberculosis lineage 7 strains are associated with prolonged patient delay in seeking treatment for pulmonary tuberculosis in Amhara Region, Ethiopia. *J Clin Microbiol*. 2015;**53**(4):1301-9.

26. Getahun M, Ameni G, Kebede A, Yaregal Z, Hailu E, Medihn G, et al. Molecular typing and drug sensitivity testing of Mycobacterium tuberculosis isolated by a community-based survey in Ethiopia. *BMC public health*. 2015;**15**(1):751.

27. Yeboah-Manu D, Asante-Poku A, Bodmer T, Stucki D, Koram K, Bonsu F, et al. Genotypic diversity and drug susceptibility patterns among M. tuberculosis complex isolates from South-Western Ghana. *PLoS One*. 2011;**6**(7):e21906.

28. Ejo M, Gehre F, Barry MD, Sow O, Bah NM, Camara M, et al. First insights into circulating Mycobacterium tuberculosis complex lineages and drug resistance in Guinea. *Infect Genet Evol*. 2015;**33**:314-9.

29. Chaoui I, Sabouni R, Kourout M, Jordaan AM, Lahlou O, Elouad R, et al. Analysis of isoniazid, streptomycin and ethambutol resistance in Mycobacterium tuberculosis isolates from Morocco. *J Infect Dev Ctries*. 2009;**3**(4):278-84.

30. Bouklata N, Supply P, Jaouhari S, Charof R, Seghrouchni F, Sadki K, et al. Molecular Typing of Mycobacterium Tuberculosis Complex by 24-Locus Based MIRU-VNTR Typing in Conjunction with Spoligotyping to Assess Genetic Diversity of Strains Circulating in Morocco. *PLoS One*. 2015;**10**(8):e0135695.

31. Chaoui I, Zozio T, Lahlou O, Sabouni R, Abid M, El Aouad R, et al. Contribution of spoligotyping and MIRU-VNTRs to characterize prevalent Mycobacterium tuberculosis genotypes infecting tuberculosis patients in Morocco. *Infect Genet Evol*. 2014;**21**:463-71.

32. Gafirita J, Umubyeyi AN, Asiimwe BB. A first insight into the genotypic diversity of Mycobacterium tuberculosis from Rwanda. *BMC Clin Pathol*. 2012;**12**:20.

33. Feuerriegel S, Oberhauser B, George AG, Dafae F, Richter E, Rusch-Gerdes S, et al. Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting. *BMC Microbiol*. 2012;**12**:90.

34. Homolka S, Post E, Oberhauser B, George AG, Westman L, Dafae F, et al. High genetic diversity among Mycobacterium tuberculosis complex strains from Sierra Leone. *BMC Microbiol*. 2008;**8**:103.

35. Mathema B, Lewis JJ, Connors J, Chihota VN, Shashkina E, van der Meulen M, et al. Molecular epidemiology of Mycobacterium tuberculosis among South African gold miners. *Ann Am Thorac Soc*. 2015;**12**(1):12-20.

36. Maningi NE, Daum LT, Rodriguez JD, Mphahlele M, Peters RP, Fischer GW, et al. Improved Detection by Next-Generation Sequencing of Pyrazinamide Resistance in Mycobacterium tuberculosis Isolates. *J Clin Microbiol*. 2015;**53**(12):3779-83.

37. Maningi NE, Malinga LA, Antiabong JF, Lekalakala RM, Mbelle NM. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa. *BMC Infect Dis*. 2017;**17**(1):795.

38. Kamudumuli PS, Beylis N, Blann L, Duse A. Molecular typing of drug-susceptible and -resistant Mycobacterium tuberculosis in Johannesburg, South Africa. *Int J Tuberc Lung Dis*. 2015;**19**(7):834-40.

39. Green E, Obi L, Nchabeleng M, De Villiers B, Sein P, Letsoalo T, et al. Molecular characterisation of resistant Mycobacterium tuberculosis isolates from Dr George Mukhari Hospital, Pretoria, South Africa. *Southern African Journal of Epidemiology and Infection*. 2008;**23**(3):11-4.

40. Dorman SE, Chihota VN, Lewis JJ, van der Meulen M, Mathema B, Beylis N, et al. Genotype MTBDRplus for direct detection of Mycobacterium tuberculosis and drug resistance in strains from gold miners in South Africa. *J Clin Microbiol*. 2012;**50**(4):1189-94.

41. Rukasha I, Said HM, Omar SV, Koornhof H, Dreyer AW, Musekiwa A, et al. Correlation of rpoB Mutations with Minimal Inhibitory Concentration of Rifampin and Rifabutin in Mycobacterium tuberculosis in an HIV/AIDS Endemic Setting, South Africa. *Front Microbiol*. 2016;**7**:1947.

42. Niehaus AJ, Mlisana K, Gandhi NR, Mathema B, Brust JC. High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa. *PLoS One*. 2015;**10**(9):e0135003.

43. Dookie N, Sturm AW, Moodley P. Moxifloxacin resistance in the F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium tuberculosis. *Infect Drug Resist*. 2014;**7**:223-8.

44. Bhembe NL, Nwodo UU, Govender S, Hayes C, Ndip RN, Okoh AI, et al. Molecular detection and characterization of resistant genes in Mycobacterium tuberculosis complex from DNA isolated from tuberculosis patients in the Eastern Cape province South Africa. *BMC Infect Dis*. 2014;**14**:479.

45. de Vos M, Muller B, Borrell S, Black PA, van Helden PD, Warren RM, et al. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. *Antimicrob Agents Chemother*. 2013;**57**(2):827-32.

46. Klopper M, Warren RM, Hayes C, Gey van Pittius NC, Streicher EM, Muller B, et al. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. *Emerg Infect Dis*. 2013;**19**(3):449-55.

47. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Bottger EC. embB306 mutations as molecular indicators to predict ethambutol susceptibility in Mycobacterium tuberculosis. *Chemotherapy*. 2012;**58**(5):358-63.

48. Sabeel S, Salih MA, Ali M, EL-Zaki S-E, Abuzeid N, Elgadi ZAM, et al. Phenotypic and Genotypic Analysis of Multidrug-Resistant Mycobacterium tuberculosis Isolates from Sudanese Patients. *Tuberculosis research and treatment*. 2017;**2017**.

49. Kibiki GS, Mulder B, Dolmans WM, de Beer JL, Boeree M, Sam N, et al. M. tuberculosis genotypic diversity and drug susceptibility pattern in HIV-infected and non-HIV-infected patients in northern Tanzania. *BMC Microbiol*. 2007;**7**:51.

50. Soudani A, Hadjfredj S, Zribi M, Messaoud T, Masmoudi A, Majed B, et al. First report of molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates from a Tunisian hospital. *Clin Microbiol Infect*. 2010;**16**(9):1454-7.

51. Soudani A, Hadjfredj S, Zribi M, Masmoudi A, Messaoud T, Tiouri H, et al. Characterization of Tunisian Mycobacterium tuberculosis rifampin-resistant clinical isolates. *J Clin Microbiol*. 2007;**45**(9):3095-7.

52. Ben Kahla I, Marzouk M, Henry M, Bedotto M, Cohen-Bacrie S, Ben Selma W, et al. Molecular characterisation of isoniazid- and rifampicin-resistant Mycobacterium tuberculosis in Central Tunisia. *Int J Tuberc Lung Dis*. 2011;**15**(12):1685-8.

53. Namouchi A, Karboul A, Mhenni B, Khabouchi N, Haltiti R, Ben Hassine R, et al. Genetic profiling of Mycobacterium tuberculosis in Tunisia: predominance and evidence for the establishment of a few genotypes. *J Med Microbiol*. 2008;**57**(Pt 7):864-72.